– AD128 is a drug combination under development by Apnimed for the treatment of Obstructive Sleep Apnea – – Phase 2 data from Apnimed’s most advanced drug candidate for Obstructive Sleep Apnea, AD109, anticipated in 2ndquarter of this year – CAMBRIDGE, Mass. May 17,...
CAMBRIDGE, Mass. April 12, 2021 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the 20th Annual...
– Morningside Ventures Joined by Seligman Investments and Tao Capital Partners – – Company expects to report topline data in Q2 2021 from two Phase 2 trials for AD109 for the treatment of OSA – – Financing will support Initiation of Phase 3 program – CAMBRIDGE,...
CAMBRIDGE, Mass. March 10, 2021 – Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that the Company’s management team will participate in the Oppenheimer 31st Annual...
– Dr. White joins Apnimed as Distinguished Scientist and Chair of the company’s Scientific Advisory Board – – Additionally, Luigi Taranto Montemurro, M.D., promoted to Chief Scientific Officer – CAMBRIDGE, Mass. March 04, 2021 – Apnimed, a clinical-stage company...
